# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the a...
Fortress Biotech, Inc. (NASDAQ:FBIO, FBIOP)))) ("Fortress"), an innovative biopharmaceutical company focused on acquiri...
Cantor Fitzgerald analyst Jennifer Kim reiterates Fortress Biotech (NASDAQ:FBIO) with a Overweight.
Mustang Bio shares soar 190.9% on high trading volume as Phase 1/2 trial data for CAR T-cell therapy MB-106 shows positive resu...
Roth MKM analyst Jason Wittes reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $10 price target.